540 related articles for article (PubMed ID: 26439366)
1. Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies.
El Zowalaty ME; Al Thani AA; Webster TJ; El Zowalaty AE; Schweizer HP; Nasrallah GK; Marei HE; Ashour HM
Future Microbiol; 2015; 10(10):1683-706. PubMed ID: 26439366
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of metallo β-lactamase producing multidrug resistant Pseudomonas aeruginosa from various clinical samples.
Ramakrishnan K; Rajagopalan S; Nair S; Kenchappa P; Chandrakesan SD
Indian J Pathol Microbiol; 2014; 57(4):579-82. PubMed ID: 25308010
[TBL] [Abstract][Full Text] [Related]
3. Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.
Neyestanaki DK; Mirsalehian A; Rezagholizadeh F; Jabalameli F; Taherikalani M; Emaneini M
Burns; 2014 Dec; 40(8):1556-61. PubMed ID: 24767143
[TBL] [Abstract][Full Text] [Related]
4. [Antibiotic susceptibility rates and beta-lactam resistance mechanisms of Pseudomonas aeruginosa strains].
Aktaş Z; Satana D; Kayacan C; Can B; Gönüllü N; Küçükbasmacı O
Mikrobiyol Bul; 2012 Jul; 46(3):386-97. PubMed ID: 22951651
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Antipseudomonal Antibiotics and Mechanisms of Multidrug Resistance in Pseudomonas aeruginosa.
El Zowalaty ME; Gyetvai B
Pol J Microbiol; 2016; 65(1):23-32. PubMed ID: 27281991
[TBL] [Abstract][Full Text] [Related]
6. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology.
Potron A; Poirel L; Nordmann P
Int J Antimicrob Agents; 2015 Jun; 45(6):568-85. PubMed ID: 25857949
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of β-lactam resistance among Pseudomonas aeruginosa.
Wolter DJ; Lister PD
Curr Pharm Des; 2013; 19(2):209-22. PubMed ID: 22894618
[TBL] [Abstract][Full Text] [Related]
8. Diversity of β-lactamases produced by imipenem resistant, Pseudomonas aeruginosa isolates from the bloodstream.
Najar Peerayeh S; Pirhajati Mahabadi R; Pakbaten Toupkanlou S; Siadat SD
Burns; 2014 Nov; 40(7):1360-4. PubMed ID: 24513132
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms.
Gad GF; El-Domany RA; Zaki S; Ashour HM
J Antimicrob Chemother; 2007 Nov; 60(5):1010-7. PubMed ID: 17906321
[TBL] [Abstract][Full Text] [Related]
10. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
[TBL] [Abstract][Full Text] [Related]
11. [Investigation of the frequency of PER-1 type beta-lactamase and antimicrobial resistance rates in nosocomial isolates of Pseudomonas aeruginosa].
Atilla A; Eroğlu C; Esen S; Sünbül M; Leblebicioğlu H
Mikrobiyol Bul; 2012 Jan; 46(1):1-8. PubMed ID: 22399165
[TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology and multidrug resistance mechanisms of Pseudomonas aeruginosa isolates from Bulgarian hospitals.
Vatcheva-Dobrevska R; Mulet X; Ivanov I; Zamorano L; Dobreva E; Velinov T; Kantardjiev T; Oliver A
Microb Drug Resist; 2013 Oct; 19(5):355-61. PubMed ID: 23600605
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.
Zavascki AP; Carvalhaes CG; Picão RC; Gales AC
Expert Rev Anti Infect Ther; 2010 Jan; 8(1):71-93. PubMed ID: 20014903
[TBL] [Abstract][Full Text] [Related]
14. Current therapies for pseudomonas aeruginosa.
Giamarellou H; Kanellakopoulou K
Crit Care Clin; 2008 Apr; 24(2):261-78, viii. PubMed ID: 18361945
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of antipseudomonal beta-lactams and aminoglycosides resistance in Pseudomonas aeruginosa during therapy.
Pagani L; Scarabelli M; Cereda PM; Debiaggi M
Microbiologica; 1987 Jan; 10(1):103-10. PubMed ID: 3106759
[TBL] [Abstract][Full Text] [Related]
16. Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.
Geisinger E; Isberg RR
J Infect Dis; 2017 Feb; 215(suppl_1):S9-S17. PubMed ID: 28375515
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic susceptibility patterns of Pseudomonas aeruginosa to available antipseudomonal drugs in Ibadan, Nigeria.
Ogbolu DO; Ogunledun A; Adebiyi OE; Daini OA; Alli AO
Afr J Med Med Sci; 2008 Dec; 37(4):339-44. PubMed ID: 19301711
[TBL] [Abstract][Full Text] [Related]
18. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.
Obritsch MD; Fish DN; MacLaren R; Jung R
Pharmacotherapy; 2005 Oct; 25(10):1353-64. PubMed ID: 16185180
[TBL] [Abstract][Full Text] [Related]
19. Characterization of acquired beta-lactamases and their genetic support in multidrug-resistant Pseudomonas aeruginosa isolates in Taiwan: the prevalence of unusual integrons.
Yan JJ; Hsueh PR; Lu JJ; Chang FY; Ko WC; Wu JJ
J Antimicrob Chemother; 2006 Sep; 58(3):530-6. PubMed ID: 16816399
[TBL] [Abstract][Full Text] [Related]
20. Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study.
Llanes C; Pourcel C; Richardot C; Plésiat P; Fichant G; Cavallo JD; Mérens A;
J Antimicrob Chemother; 2013 Aug; 68(8):1763-71. PubMed ID: 23629014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
